Umoja Biopharma is blazing a new trail for the immunotherapy approach by providing scalable, more effective, more accessible CAR T-cell treatments. With a $53 million launch today, the company’s team is coming together to deliver something incredible.
Like many biotechs right now, Umoja is focused on immunotherapies. But unlike their competitors, Umoja’s approach to T-cell engineering is completely unique. It will re-engineer a patient’s own immune system in vivo to attack and destroy hematologic and solid organ-based tumors.